ATARA Biotherapeutics (NASDAQ: ATRA) reported Q4 EPS of ($0.95), $0.21 worse than the analyst estimate of ($0.74).

“Atara had a very strong year in 2020, delivering on key milestones across the Company’s three strategic priorities,” said Pascal Touchon, President and Chief Executive Officer of Atara. “We anticipate several additional key catalysts over the next 18 months, especially the completion of the tab-cel® BLA filing in Q3 2021, significant advancement on the ATA188 program - including long-term clinical data update from the Phase 1 study as well as enrollment progress in the Phase 2 RCT enabling an interim analysis, and preclinical and clinical progress on both the mesothelin and CD19 CAR T programs.”

For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.